FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer’s disease

Stockholm, 23 June 2021 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease.

The release as fetched from its publisher. bioarctic.com ↗